Trial Profile

MicroBLITZ: Microtransplantation and Checkpoint Blockade Immunotherapy for Relapsed or Refractory B Cell Lymphomas

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 04 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nivolumab (Primary)
Indications B-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Hodgkin's disease; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Waldenstrom's macroglobulinaemia
Focus Adverse reactions
Acronyms MicroBLITZ

Most Recent Events

19 Mar 2021 Planned initiation date changed from 31 Dec 2019 to 10 Jul 2020.
19 Mar 2021 Status changed from recruiting to discontinued due to lack of accrual.
24 Feb 2020 Planned primary completion date changed from 15 May 2023 to 15 Mar 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com